{
    "clinical_study": {
        "@rank": "21779", 
        "arm_group": [
            {
                "arm_group_label": "Enzalutamide & exemestane", 
                "arm_group_type": "Experimental", 
                "description": "Enzalutamide 160 mg/day administered as four 40-mg soft gelatin capsules by mouth once daily with or without food and exemestane 50mg tablet once daily after food."
            }, 
            {
                "arm_group_label": "placebo & exemestane", 
                "arm_group_type": "Active Comparator", 
                "description": "placebo and exemestane 25 mg once daily after food."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if enzalutamide given in combination with\n      exemestane is safe and effective in patients with advanced breast cancer."
        }, 
        "brief_title": "Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of\n      Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced\n      Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willing and able to provide informed consent;\n\n          -  Postmenopausal;\n\n          -  Advanced histologically confirmed breast cancer that is ER+, PgR+, or both, and HER-2\n             normal;\n\n          -  Up to one prior hormone therapy and up to one prior chemotherapy in the advanced\n             setting is allowed;\n\n          -  Availability of a representative, formalin-fixed, paraffin-embedded tumor specimen\n             that enabled the diagnosis of breast cancer with viable tumor cells in a tissue block\n             or unstained serial slides accompanied bay an associated pathology report;\n\n          -  Measurable disease. Patients with non-measurable bone or skin disease as their only\n             manifestation of advanced breast cancer are also eligible;\n\n          -  ECOG status of 0 or 1;\n\n        Exclusion Criteria:\n\n          -  Any severe concurrent disease, infection, or comorbid condition that renders the\n             patient inappropriate for enrollment in the opinion of the investigator;\n\n          -  Any condition or reason that interferes with the patient's ability to participate in\n             the trial, that may cause undue risk, or complicates the interpretation of safety\n             data, in the opinion of the investigator;\n\n          -  Current or previously treated brain metastasis or leptomeningeal disease;\n\n          -  Prior therapy (> 28 days) with exemestane in the metastatic setting (Patients\n             receiving exemestane in the adjuvant setting and having disease recurrence more than\n             1 year after treatment discontinuation are eligible);\n\n          -  Requires treatment for tuberculosis or HIV infection;\n\n          -  Radiation therapy within 7 days before randomization;\n\n          -  History of another invasive cancer within 5 years before randomization;\n\n          -  History of seizure or any condition that may predispose to seizure;\n\n          -  Clinically significant cardiovascular disease;\n\n          -  Active gastrointestinal disorder;\n\n          -  Major surgery within 28 days prior to randomization;\n\n          -  Treatment with any oral anticancer or  with any non-hormonal anticancer agent within\n             14 days before randomization;\n\n          -  Treatment with any approved or investigational agent that blocks androgen synthesis\n             or targets the androgen receptor;\n\n          -  Treatments with any  of the following medications within 14 days before\n             randomization: Estrogens, Androgens, or Systemic radionuclides;\n\n          -  Hypersensitivity reaction to exemestane."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02007512", 
            "org_study_id": "MDV3100-12"
        }, 
        "intervention": [
            {
                "arm_group_label": "Enzalutamide & exemestane", 
                "description": "160 mg/day administered as four 40-mg soft gelatin capsules by mouth once daily with or without food.", 
                "intervention_name": "Enzalutamide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "MDV3100", 
                    "XTANDI"
                ]
            }, 
            {
                "arm_group_label": [
                    "Enzalutamide & exemestane", 
                    "placebo & exemestane"
                ], 
                "description": "25 mg or 50 mg tablet administered as a single capsule by mouth once daily after food.", 
                "intervention_name": "exemestane", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo & exemestane", 
                "description": "Sugar pill manufactured to mimic enzalutamide administered as four soft gelatin capsules by mouth once daily with or without food.", 
                "intervention_name": "Placebo (for enzalutamide)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Estrogens", 
                "Progesterone", 
                "Exemestane"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "advanced breast cancer", 
            "enzalutamide", 
            "MDV3100", 
            "Estrogen receptor positive", 
            "Progesterone receptor positive", 
            "HER-2 normal"
        ], 
        "lastchanged_date": "March 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lakewood", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80228"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Myers", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33901"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33705"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55407"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morristown", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07962"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45242"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29605"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38120"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77024"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tyler", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75702"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "230502"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23230"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal", 
        "other_outcome": [
            {
                "description": "Assessments of health-related quality of life will be performed using the European Organization for Research and Treatment of Cancer (EORTC) quality-of-life core questionnaire (QLQ-C30) and breast cancer module(QLQ-BR23) at specified intervals and at time of disease progression.", 
                "measure": "Health-related Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "24 Months"
            }, 
            {
                "description": "To determine the percent of androgen receptor (AR) nuclear expression and signaling in breast tissue and to evaluate the relationship of this expression with enzalutamide effects on circulating tumor biomarkers, circulating hormones, and clinical outcomes.", 
                "measure": "Androgen Receptor (AR) Expression by Immunohistochemistry  (IHC)", 
                "safety_issue": "No", 
                "time_frame": "24 Months"
            }
        ], 
        "overall_contact": {
            "email": "breastcancertrials@medivation.com", 
            "last_name": "Jane Dennison", 
            "phone": "855-349-1891"
        }, 
        "overall_contact_backup": {
            "email": "mdv3100_12@medivation.com", 
            "last_name": "Amy Grekowicz, MPH", 
            "phone": "(415) 543-3470"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the benefit of exemestane plus enzalutamide versus exemestane plus placebo as assessed by progression-free survival (PFS) in patients with advanced breast cancer that is estrogen or progesterone receptor-positive or both (ER+/PgR+) and human epidermal growth factor receptor 2 (HER2)-normal", 
            "measure": "Progression Free Survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "24 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02007512"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Clinical benefit rate, defined as the proportion of patients with a best response of complete response(CR), partial response (PR), or of stable disease (SD) lasting \u2265 24 weeks;\nBest objective response rate;\nDuration of response;\nTime to response;\nTime to progression;\nPFS rate at 6 months.", 
                "measure": "Clinical Benefit Rate", 
                "safety_issue": "No", 
                "time_frame": "24 Months"
            }, 
            {
                "description": "Cmax for enzalutamide and exemestane one hour pre dose and exemestane 6 hours post dose at specified study visits.", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Medivation, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Medivation, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}